Repligen Corporation (RGEN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Repligen Corporation (RGEN) has a cash flow conversion efficiency ratio of 0.023x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($48.10 Million) by net assets ($2.08 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See RGEN equity financing ratio to measure how much of total assets are equity-financed.
Repligen Corporation - Cash Flow Conversion Efficiency Trend (1990–2024)
This chart illustrates how Repligen Corporation's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Repligen Corporation cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Repligen Corporation Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Repligen Corporation ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
SHIMANO INC. UNSP.ADR/10
F:SHM1
|
N/A |
|
MITSU.CH.GRP ADR/5
F:M3C0
|
N/A |
|
ENN Ecological Holdings Co Ltd
SHG:600803
|
0.023x |
|
Yunnan Yuntianhua Co Ltd
SHG:600096
|
0.023x |
|
Corporacion Acciona Energias Renovables SA
MC:ANE
|
0.011x |
|
Hanwha Systems Co Ltd
KO:272210
|
-0.044x |
|
Tetra Tech Inc
NASDAQ:TTEK
|
0.089x |
|
The Magnum Ice Cream Company N.V.
AS:MICC
|
0.153x |
Annual Cash Flow Conversion Efficiency for Repligen Corporation (1990–2024)
The table below shows the annual cash flow conversion efficiency of Repligen Corporation from 1990 to 2024. For the full company profile with market capitalisation and key ratios, see RGEN market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $1.97 Billion | $175.39 Million | 0.089x | +53.85% |
| 2023-12-31 | $1.97 Billion | $113.92 Million | 0.058x | -35.83% |
| 2022-12-31 | $1.91 Billion | $172.08 Million | 0.090x | +32.43% |
| 2021-12-31 | $1.75 Billion | $119.02 Million | 0.068x | +66.06% |
| 2020-12-31 | $1.53 Billion | $62.62 Million | 0.041x | -35.43% |
| 2019-12-31 | $1.06 Billion | $67.22 Million | 0.063x | +103.79% |
| 2018-12-31 | $-19.60 Million | $32.77 Million | -1.672x | -201.82% |
| 2017-12-31 | $-31.51 Million | $17.45 Million | -0.554x | -1342.81% |
| 2016-12-31 | $168.76 Million | $7.52 Million | 0.045x | -63.66% |
| 2015-12-31 | $122.75 Million | $15.05 Million | 0.123x | +154.64% |
| 2014-12-31 | $-81.99 Million | $18.40 Million | -0.224x | -189.92% |
| 2013-12-31 | $103.89 Million | $25.93 Million | 0.250x | +56.24% |
| 2012-12-31 | $84.12 Million | $13.44 Million | 0.160x | +356.45% |
| 2011-12-31 | $66.00 Million | $2.31 Million | 0.035x | -27.35% |
| 2010-12-31 | $67.09 Million | $3.23 Million | 0.048x | +230.28% |
| 2009-12-31 | $66.21 Million | $-2.45 Million | -0.037x | -140.13% |
| 2008-12-31 | $68.46 Million | $6.31 Million | 0.092x | -84.62% |
| 2007-12-31 | $64.21 Million | $38.47 Million | 0.599x | +3496.62% |
| 2006-12-31 | $24.34 Million | $405.48K | 0.017x | +0.50% |
| 2005-12-31 | $25.06 Million | $415.38K | 0.017x | +150.94% |
| 2004-12-31 | $24.44 Million | $-795.28K | -0.033x | +85.04% |
| 2003-12-31 | $26.30 Million | $-5.72 Million | -0.217x | -25.49% |
| 2002-12-31 | $30.34 Million | $-5.26 Million | -0.173x | +2.07% |
| 2001-12-31 | $26.87 Million | $-4.75 Million | -0.177x | -12.91% |
| 2000-12-31 | $29.48 Million | $-4.62 Million | -0.157x | -75.15% |
| 1999-12-31 | $35.03 Million | $-3.13 Million | -0.089x | +70.15% |
| 1998-12-31 | $4.00 Million | $-1.20 Million | -0.300x | -126.98% |
| 1997-12-31 | $5.30 Million | $-700.00K | -0.132x | +73.58% |
| 1996-12-31 | $6.40 Million | $-3.20 Million | -0.500x | +73.66% |
| 1995-12-31 | $4.90 Million | $-9.30 Million | -1.898x | -102.80% |
| 1994-12-31 | $15.60 Million | $-14.60 Million | -0.936x | -7.18% |
| 1993-12-31 | $28.40 Million | $-24.80 Million | -0.873x | -1517.79% |
| 1992-12-31 | $35.20 Million | $-1.90 Million | -0.054x | +67.61% |
| 1991-12-31 | $51.60 Million | $-8.60 Million | -0.167x | -50.29% |
| 1990-12-31 | $51.40 Million | $-5.70 Million | -0.111x | -- |
About Repligen Corporation
Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company also provides chromatography products, including OPUS pre-pack… Read more